Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities.

Molecular cancer - 19 Feb 2018

Kleczko Emily K, Heasley Lynn E

Abstract excerpt

Receptor tyrosine kinase (RTK) pathways serve as frequent oncogene drivers in solid cancers and small molecule and antibody-based inhibitors have been developed as targeted therapeutics for many of these oncogenic RTKs. In general, these drugs, when delivered as single agents in a manner consistent with the principles of precision medicine, induce tumor shrinkage but rarely complete tumor elimination. Moreover,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Transformation, Neoplastic
Share to Cellular Reprogramming

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Leukemic

Share to Molecular Targeted Therapy

Share to Neoplasms

Share to Protein Kinase Inhibitors

Share to Receptor Protein-Tyrosine Kinases

Share to Signal Transduction

Source

Open in PubMed Open full text

Identifiers

PMID: 29458371
DOI: 10.1186/s12943-018-0816-y
PMCID: PMC5817864

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities.PMID 29458371Read ↗

Drug-tolerant persister cell in cancer: reversibility, microenvironmental interplay, and therapeutic strategiesSemantic proximity Read ↗

Tolerant/Persister Cancer Cells and the Path to Resistance to Targeted Therapy.Semantic proximity Read ↗

A safe haven for cancer cells: tumor plus stroma control by DYRK1BSemantic proximity Read ↗

Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer BiologySemantic proximity Read ↗

FGFR blockade inhibits targeted therapy-tolerant persister cells in basal FGFR1 and FGF2 high expressing cancers with driver oncogenesSemantic proximity Read ↗

Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistanceSemantic proximity Read ↗

Targeted Therapies in Cancer: To Be or Not to Be, SelectiveSemantic proximity Read ↗

Tumor cell-intrinsic phenotypic plasticity facilitates adaptive cellular reprogramming driving acquired drug resistanceSemantic proximity Read ↗

Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategiesSemantic proximity Read ↗

Transient cell-in-cell formation underlies tumor resistance to immunotherapySemantic proximity Read ↗

Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment.Semantic proximity Read ↗

Strategies to overcome drug resistance of receptor tyrosine kinaseaddicted cancer cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.